A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
Obesity is a growing global health concern that leads to metabolic imbalances and progressive cardiac remodelling. This study investigated whether semaglutide (SMG) can counteract the disruption to the gut-heart-metabolic axis and associated myocardi…
PURPOSE OF REVIEW: This article reviews the evidence for cardiovascular and renal risk reduction with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes mellitus (T2DM), based on randomized controlled trials, including emerging…
Sublingual delivery of peptide therapeutics is hindered by mucosal barriers and poor bioavailability. This study aimed to evaluate and optimize sublingual administration of TE-8105, a long-acting dual fatty acid-conjugated GLP-1 receptor agonist that…
IMPORTANCE: Heart failure (HF) is a common complication of type 2 diabetes (T2D). Oral semaglutide reduced the risk of major adverse cardiovascular (CV) events (MACE; comprising CV death, nonfatal myocardial infarction, or nonfatal stroke) in people…
OBJECTIVE: This study aims to evaluate the quality, reliability, and content characteristics of semaglutide-related short videos on three major Chinese short-video platforms (Bilibili, TikTok, and Rednote), with a focus on exploring differences in th…
BACKGROUND AND OBJECTIVES: Individuals with type 2 diabetes mellitus (T2DM) are at an increased risk of developing epilepsy, particularly in later life. While preclinical studies suggest neuroprotective properties of glucagon-like peptide-1 receptor…
Semaglutide has demonstrated beneficial effects in patients with type 2 diabetes; however, its long-term impact on skeletal muscle remains uncertain, particularly in individuals with multiple risk factors for muscle decline. We report a case of a 65-…
Obesity and hypertension are interdependent chronic conditions that substantially elevate global cardiovascular risk. Rising obesity prevalence has led to a parallel increase in hypertension, driven by complex physiological disturbances that extend b…
AIMS: Treatment options for adolescents with obesity are limited, and some may benefit from lower maintenance doses of semaglutide. This study used model-informed drug development (MIDD) to evaluate whether a 1.7-mg maintenance dose provides comparab…
Pulmonary delivery provides a noninvasive route for systemic administration of biologics, yet efficient lung deposition and permeation across pulmonary barriers remain major challenges. In this study, morphology-engineered zinc oxide (ZO) biointeract…
OBJECTIVE: Adjunctive use of tirzepatide or semaglutide has demonstrated benefits in improving glucose control (HbA1c, Time in Range), reducing body weight, and insulin requirements, in overweight (OW) or obese (OB) adults with type 1 diabetes (T1D).…
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are therapies for type 2 diabetes whose use expanded sharply after semaglutide's 2021 approval for obesity. Although gastrointestinal effects are well described, national patterns of…
AIMS: To describe obesity treatments in real-world settings after discontinuation of semaglutide or tirzepatide and variability in weight change post-discontinuation. MATERIALS AND METHODS: This retrospective cohort study used electronic health recor…
OBJECTIVE: This study aimed to describe real-world obesity medication (OM) prescribing and dispensing among adolescents and young adults (AYAs) and examine factors associated with dispensing. METHODS: A retrospective cohort linked Nemours Children's…
BACKGROUND: Menstrual health is a critical marker of physiological and psychological well-being in adolescents. While undernutrition and energy deficiency are well-known causes of menstrual disruption through hypothalamic hypogonadal suppression, the…
Blood glucose homeostasis relies on coordinated rhythmic activity across pancreatic islets. Glucose triggers islet rhythmicity, but population-level dynamics in pancreases in vivo remain unclear. Using simultaneous multi-islet Caimaging in mice and t…
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease closely associated with obesity and metabolic dysfunction, which contribute to increased disease severity, reduced treatment response, and impaired quality of life. Incretin-based t…